Gene Variant Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene RET
Variant L790F
Impact List missense
Protein Effect unknown
Gene Variant Descriptions RET L790F lies within the protein kinase domain of the Ret protein (UniProt.org). L790F results in ligand-independent phosphorylation of Ret (PMID: 15184865, PMID: 23526464), however, also results in cell proliferation and transformation activity similar to wild-type Ret in cell culture (PMID: 21810974, PMID: 32546069), and therefore, its effect on Ret protein function is unknown.
Associated Drug Resistance
Category Variants Paths

RET mutant RET L790X RET L790F

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_020975.6
gDNA chr10:g.43118458G>T
cDNA c.2370G>T
Protein p.L790F
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
NM_020630.7 chr10:g.43118458G>T c.2370G>T p.L790F RefSeq GRCh38/hg38
NM_001406744.1 chr10:g.43118458G>T c.2370G>T p.L790F RefSeq GRCh38/hg38
NM_020975.5 chr10:g.43118458G>T c.2370G>T p.L790F RefSeq GRCh38/hg38
NM_020975.6 chr10:g.43118458G>T c.2370G>T p.L790F RefSeq GRCh38/hg38
NM_020630 chr10:g.43118458G>T c.2370G>T p.L790F RefSeq GRCh38/hg38
NM_001406760.1 chr10:g.43118458G>T c.2370G>T p.L790F RefSeq GRCh38/hg38
NM_020630.5 chr10:g.43118458G>T c.2370G>T p.L790F RefSeq GRCh38/hg38
NM_001406759.1 chr10:g.43118458G>T c.2370G>T p.L790F RefSeq GRCh38/hg38
NM_020975 chr10:g.43118458G>T c.2370G>T p.L790F RefSeq GRCh38/hg38
NM_001406743.1 chr10:g.43118458G>T c.2370G>T p.L790F RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
RET L790F Advanced Solid Tumor sensitive Ponatinib Preclinical Actionable In a preclinical study, Iclusig (ponatinib) inhibited phosphorylation of Ret in transformed human cells expressing RET L790F in culture (PMID: 23526464). 23526464
RET L790F Advanced Solid Tumor sensitive Vandetanib Preclinical Actionable In a preclinical study, Caprelsa (vandetanib) inhibited Ret autophosphorylation in transformed cells expressing RET L790F in culture (PMID: 15184865). 15184865
RET L790F medullary thyroid carcinoma predicted - sensitive Selpercatinib Case Reports/Case Series Actionable In a clinical case study, Retevmo (selpercatinib) treatment resulted in a partial response in a pediatric patient with medullary thyroid carcinoma harboring RET L790F (PMID: 38844796; NCT03336931). 38844796